[123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: A meta-analysis

European Journal of Neurology

Volumn 21, Issue 11, 2014, Pages 1369-e90

  Brigo, F ^a,b   Matinella, A ^b   Erro, R ^b,c   Tinazzi, M ^b  

^a Ospedale Tappeiner   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

DaTSCAN; Drug induced parkinsonism; Idiopathic Parkinson's disease; Single photon emission computed tomography; Unclear parkinsonism; Vascular parkinsonism

Indexed keywords

IOFLUPANE I 123; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; TROPANE DERIVATIVE;

ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DOPAMINERGIC SYSTEM; DRUG INDUCED DISEASE; DRUG INDUCED PARKINSONISM; HUMAN; META ANALYSIS; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMATIC REVIEW; VASCULAR PARKINSONISM; AGED; CHEMICALLY INDUCED; DIAGNOSTIC USE; MIDDLE AGED; SCINTISCANNING; STANDARDS;

AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MIDDLE AGED; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84908669402     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12444     Document Type: Article

References (41)

1. Rajput A, Rozdilsky B, Ang L. Accuracy of clinical diagnosis in parkinsonism - a prospective study. Can J Neurol Sci 1991; 18: 275-278.
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
3. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol 1993; 50: 140-148.
4. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497-1499.
5. Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26: 171-182.
6. Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinsonism Relat Disord 2007; 13(Suppl. 3): S425-S428.
7. Vlaar AM, van Kroonenburgh MJ, Kessels AG, Weber WE. Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes. BMC Neurol 2007; 7: 27.
8. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med 2004; 140: 189-202.
9. Booij J, Teune LK, Verberne HJ. The role of molecular imaging in the differential diagnosis of parkinsonism. Q J Nucl Med Mol Imaging 2012; 56: 17-26.
10. Sommer U, Hummel T, Cormann K, et al. Detection of presymptomatic Parkinson's disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004; 19: 1196-1202.
11. Piccini P, Whone A. Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol 2004; 3: 284-290.
12. Tinazzi M, Ottaviani S, Isaias IU, et al. [123I]FP-CIT SPET imaging in drug-induced parkinsonism. Mov Disord 2008; 23: 1825-1829.
13. Antonini A, Vitale C, Barone P, et al. The relationship between cerebral vascular disease and parkinsonism: the VADO study. Parkinsonism Relat Disord 2012; 18: 775-780.
14. 3I]FP-CIT single photon emission computed tomography findings in drug-induced parkinsonism. Schizophr Res 2012; 139: 40-45.
15. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006; 6: 9.
16. Lijmer JG, Mol BW, Heisterkamp S, et al. Empirical evidence of design-related bias in studies of diagnostic tests. JAMA 1999; 282: 1061-1066.
17. Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991; 44: 763-770.
18. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-872.
19. Devillé WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002; 2: 9.
20. Zamora J, Muriel A, Abraira V. Statistical methods. 2006. Available at: ftp://ftp.hrc.es/pub/programas/metadisc/MetaDisc_StatisticalMethods.pdf (accessed 14/05/2013).
21. Egger M, Smith GD, Altman DG. Systematic Reviews in Health Care. London: BMJ Publishing Group, 2005: 271.
22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
23. Zamora J, Abraira V, Muriel A, Khan KS, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006; 6: 31.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
25. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993; 12: 1293-1316.
26. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266-272.
27. Manoharan P, Jamieson S, Bury RF. Initial clinical experience with [123I]ioflupane scintigraphy in movement disorders. Clin Radiol 2007; 62: 463-471.
28. Vlaar AM, de Nijs T, van Kroonenburgh MJ, et al. The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurol 2008; 8: 42.
29. Vlaar AM, de Nijs T, Kessels AG, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol 2008; 59: 258-266.
30. Bouwmans AE, Vlaar AM, Mess WH, Kessels A, Weber WE. Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients. BMJ Open 2013; 3: e002613.
31. McGee SR. Diagnostic accuracy of physical findings. In: McGee SR, ed. Evidence-Based Physical Diagnosis. Philadelphia, PA: Saunders Elsevier, 2007: 3-19.
32. Bajaj N, Hauser RA, Grachev ID. Clinical utility of dopamine transporter single photon emission CT (DaT-SPECT) with (123I) ioflupane in diagnosis of parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2013; 84: 1288-1295.
33. Thanvi B, Robinson T. Vascular parkinsonism - an important cause of parkinsonism in older people. Age Ageing 2005; 34: 114-119.
34. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord 2010; 25: 49-56.
35. Gershanik OS. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs Aging 1994; 5: 127-132.
36. Fleming P, Makar H, Hunter KR. Levodopa in drug-induced extrapyramidal disorders. Lancet 1970; 2: 1186.
37. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug induced and psychogenic parkinsonism. Mov Disord 2003; 18(Suppl. 7): S28-S33.
38. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006; 21: 510-514.
39. Mateos JJ, Lomeña F, Parellada E, et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology 2007; 191: 805-811.
40. de la Fuente-Fernández R. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012; 78: 696-701.
41. US FDA. PCNS Advisory Committee Briefing Document. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/.../UCM176192.pdf (accessed 24/01/2014).